Knocking out ITGA4 restored the sensitivity of BCR-ABL+ murine leukemia toward nilotinib (NTB), and a blockade of integrin alpha 4 with a monoclonal antibody sensitized primary B-ALL engrafted xenograft mice to chemotherapy (175). The gene discussed is ABL1; the disease is leukemia.